Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Disrupted synaptic vacuolar H+-ATPase renders synaptic vulnerability to Alzheimer’s disease
Yanting Chen, Khloud Ashraf Farouk Emam, Shuwen Yue, Jing Tian, Tienju Wang, Albert Park, Shalini Mishra, Gagan Deep, Zi-Jun Wang, Heng Du, Lan Guo
Yanting Chen, Khloud Ashraf Farouk Emam, Shuwen Yue, Jing Tian, Tienju Wang, Albert Park, Shalini Mishra, Gagan Deep, Zi-Jun Wang, Heng Du, Lan Guo
View: Text | PDF
Research Article Aging Neuroscience

Disrupted synaptic vacuolar H+-ATPase renders synaptic vulnerability to Alzheimer’s disease

  • Text
  • PDF
Abstract

Defective synaptic transmission is a prominent pathology that underlies cognitive deficits in Alzheimer’s disease (AD), highlighting the need to elucidate molecular mechanisms of synaptic failure. Vacuolar H+-ATPase (V-ATPase), a proton-pumping enzyme, is essential for synaptic vesicle acidification and neurotransmitter loading. However, whether SV-associated V-ATPase is vulnerable to AD remains unclear. Here, using SV-rich fractions from postmortem brain tissues, we identified SV-associated V-ATPase deficits, including decreased enzymatic activity, impaired complex assembly, and altered expression of its key subunits in AD. SV-associated V-ATPase dysfunction was further associated with pathological and clinical characteristics of AD. Genetic downregulation of the V-ATPase V1D subunit, a component reduced in AD brains, disrupted V-ATPase proton transport and impaired SV acidification. Further experiments using 5×FAD mice, which exhibited AD-like SV-associated V-ATPase deficits, demonstrated the deleterious impact of V-ATPase dysfunction on SV acidification and synaptic transmission including presynaptic neurotransmitter release. In addition, ex vivo studies identified amyloid β–induced oxidative stress as a driver of V1D loss and V-ATPase disassembly, linking AD pathology to SV-associated V-ATPase dysfunction. These findings indicate that SV-associated V-ATPase dysfunction contributes to synaptic failure and cognitive deficits in AD. Therapeutic avenues to mitigate V-ATPase dysfunction have the potential to attenuate synaptic failure for the management of AD.

Authors

Yanting Chen, Khloud Ashraf Farouk Emam, Shuwen Yue, Jing Tian, Tienju Wang, Albert Park, Shalini Mishra, Gagan Deep, Zi-Jun Wang, Heng Du, Lan Guo

×

Figure 7

Aβ-induced oxidative stress promotes V-ATPase disassembly in SVs via V1D loss.

Options: View larger image (or click on image) Download as PowerPoint
Aβ-induced oxidative stress promotes V-ATPase disassembly in SVs via V1D...
(A) Immunoblot analysis of V1D in SV-rich fractions from ex vivo–cultured organotypic brain slices treated with oligomeric Aβ42 (500 μM) and/or NAC (500 μM or 1 mM), normalized to synaptophysin. One-way ANOVA followed by Bonferroni’s post hoc test. n = 3 per group. (B) Assessment of V-ATPase complex assembly in SV-rich fractions based on detection of V0c subunit. One-way ANOVA followed by Bonferroni’s post hoc test. n = 5 in control and Aβ groups; n = 3 in Aβ + NAC 500 μM and Aβ + NAC 1 mM groups.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts